Prothena Reports Full Year 2025 Results, Details Restructuring Impact, and Projects Significantly Reduced 2026 Cash Burn
Summary
Prothena reported a $244.1 million net loss for 2025, driven by a Phase 3 program discontinuation and a 63% workforce reduction, but projects a significantly reduced cash burn of $50-$55 million for 2026, while advancing multiple partnered clinical programs.
Key Events
-
Full Year 2025 Financial Results
Reported a net loss of $244.1 million for the year ended December 31, 2025, with total revenue of $9.7 million. The accumulated deficit reached $1.3 billion.
-
Significant Restructuring and Program Discontinuation
Discontinued the Birtamimab development program in May 2025 due to Phase 3 trial results and implemented an approximate 63% workforce reduction in June 2025, with further reductions of 17 employees expected in 2026.
-
Projected Reduced Cash Burn for 2026
Forecasts net cash used in operating and investing activities to be approximately $50 million to $55 million for 2026, a significant reduction from the $163.6 million used in operating activities in 2025.
-
Advancement of Partnered Clinical Pipeline
Partners initiated Phase 3 trials for Prasinezumab (Parkinson's disease) and Coramitug (ATTR amyloidosis), and a Phase 2 trial for BMS-986446 (Alzheimer's disease). A new Phase 1 trial for PRX019 (neurodegenerative diseases) was also initiated with BMS, including an $80 million option exercise fee and potential milestones up to $617.5 million.
Analysis
This annual report provides a comprehensive financial and operational update for Prothena, highlighting a year of significant strategic shifts. While the company reported a substantial net loss and accumulated deficit for 2025, driven by the discontinuation of the Birtamimab program and a major workforce reduction, it also projects a significantly lower cash burn for 2026. This improved cash runway, coupled with ongoing advancements in its partnered pipeline programs (two in Phase 3, one in Phase 2, and a new Phase 1), indicates the company is actively managing its resources and progressing its core assets despite past setbacks. The full valuation allowance on deferred tax assets reflects a cautious outlook on future profitability. Investors should monitor the progress of the clinical trials and the company's ability to secure additional capital on favorable terms.
At the time of this filing, PRTA was trading at $9.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $466.7M. The 52-week trading range was $4.32 to $16.16. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.